AMGEN PRESENTS LATE-BREAKING PHASE 2 OLPASIRAN DATA AT ESC 2023
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced data from the final analysis of the Phase 2 OCEAN(a)-DOSE study of olpasiran, a small interfering RNA...
Source: prnewswire.com
Extension Program On Long News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Extension Program On Long. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Extension Program On Long Today - Breaking & Trending Today